Centro De Ingenieria Genetica Y Biotecnologia

Centro De Ingenieria Genectica Y Biotecnologia

Diana Garcia Del Barco Herrera

Gerardo Enrique Guillen Nieto

Jorge Amador Berlanga Acosta

Sonia Gonzalez Blanco

Danay Cibrian Vera

Mario Pablo Estrada Garcia

Gerardo Enrique Guillén Nieto

Julio Raul Fernandez Masso

Luis Saturnino Herrera Martinez

Rebeca Martinez Rodriguez

Raimundo Ubieta Gomez

Jose Ignacio Fernandez Montequin

Jorge Berlanga Acosta

Vivian Maria Saez Martinez

Osvaldo Reyes Acosta

Glay Chinea Santiago

Alexis Musacchio Lasa

Raimundo Ubieta Gómez

Eduardo Penton Arias

Pedro Antonio Lopez Saura

Mariela Vazquez Castillo

Manuel Selman-Housein Sosa

Ania De La Nuez Veulens

Rolando Eduardo Rodriguez Fernandez

Ernesto Lopez Mola

Giselle Penton Rol

José Suarez Alba

Francisco Hernández Bernal

Jose Suarez Alba

Isabel Guillen Perez

Carmen Maria Valenzuela Silva

Majel Cervantes Llanos

Juan Valiente Mustelier

Dania Mercedes BacardÍ FERNÁNDEZ

Yasser ZÁRATE Rivera

Héctor Jesús Santana MILIÁN

Raimundo Ubieta GÓMEZ

Francisco HERNÁNDEZ Bernal

Gerardo Enrique GUILLÉN Nieto

Vivian María SÁEZ MARTÍNEZ

José Ignacio Fernández Montequín

The present invention is related to the use of the growth hormone releasing peptide-6 (GHRP-6) for the manufacture of a late cardioprotective and cardiac restoration medicament. Said late cardioprotective and cardiac restoration medicament comprises GHRP-6 and a pharmaceutically acceptable excipient or vehicle. It also provides a method for the treatment of a disease that involves a low cardiac output, wherein a therapeutically effective amount of a late cardioprotective and cardiac restoration medicament comprising GHRP-6 is administered to a subject in need. Said medicament allows treating in a late manner, even days later, the myocardium that suffered episodes of stunning, hibernation, ischemia and its consequences thereof.

Use of GHRP-6 as late cardioprotective and cardiac restoration medicament

The present invention is relevant to human medicine, and, in particular, to the use of Epidermal Growth Factor (EGF) in a pharmaceutical composition, said composition is administered through infiltration at the periphery of nerve trunks and/or ganglia, for the morphofunctional restoration of peripheral nerves in painful, sensory-motor neuropathy, as well as ischemic neuritis. It is also relevant to an EGF containing composition, where this molecule can be formulated together with anesthetic or analgesic drugs, or encapsulated in microspheres, and their use for the morphofunctional restoration of peripheral nerves in painful, sensory-motor neuropathy, as well as in ischemic neuritis.

Use of epidermal growth factor for the morphofunctional restoration of peripheral nerves in diabetic neuropathy

The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms of cutaneous fibrosis of any etiopathogenesis. Additionally, these peptides prevent and eradicate deposition of amiloid and hyaline materials in any of their correspondent chemical forms and tissue manifestations in the brain, cerebellum, blood vessels, liver, intestines, kidneys, spleen, pancreas, joints and the skin, among others. By this way, cellular, tissular and organ dysfunctions generated by these depositions are corrected. The peptides of the present invention are infiltrated or topically applied, contributing to prevent and eradicate keloids and hypertrophic scars in the skin, derived as sequelae of burns and other cutaneous trauma.

Method for controlling fibrosis and other pathological deposits in tissues comprising administering a GHRP-6 composition

The invention relates to human medicine and to the use of epidermal growth factor (EGF) for preparing a pharmaceutical composition which is administered by infiltration into the periphery of nerve ganglia and/or trunks for the morphofunctional restoration of peripheral nerves in painful sensory-motor neuropathy as well as manifestations of ischemic neuritis. The invention also includes a composition containing EGF which can be formulated together with anesthetics or analgesics or encapsulated in microspheres and to the use thereof for the morphofunctional restoration of peripheral nerves in painful sensitive-motor-type diabetic neuropathy and the manifestations of ischemic neuritis.

Peptidic chemical compounds obtained by in silico molecular modelling, having a structure that enables them to perform the same functions of peptidic growth hormone secretagogues. The invention also comprises the preparations containing such compounds and the use in medicines, food additives, nutritional supplements or other formulations of human or animal use.

Peptidic growth hormone secretagogues analog compounds and preparations thereof

The present invention consists of the combination of Interferon alpha and C-Phycocyanin (IFN-&#x3b1;/C-Phyco) for obtaining a pharmaceutical preparation for autoimmune disease, allergy and cancer treatments. The anti-inflammatory, immunomodulator, antioxidant, anti-viral, anti-proliferative and anti-tumoral effects, associated to the regulatory T cell inducer effect demonstrated in this invention is the rationale for the use of the IFN-&#x3b1;/C-Phyco combination in these diseases.

Treatment of multiple sclerosis by administration of interferon alpha and C-phycocyanin

This invention relates to a medicine for humans, and particularly to a pharmaceutical combination comprising Epidermal Growth Factor (EGF) and Growth Hormone secretagogue hexapeptide (GHRP) for use in preventing tissue damage due to blood flow suppression by enhancing tissue repair following ischemic damage. The aforementioned combination may be applied as a single pharmaceutical composition. Alternatively, an individual may also receive both EGF and GHRP in a separate manner but within a single therapeutic regime to enhance cellular survival when organs are subjected to blood flow deprivation for a critical period of time. This combination attenuates reactive oxygen species (ROS) formation and its associated cytotoxicity. It is also useful in promoting cellular survival when tissue or organs are exposed to prolonged ischemic periods. The combination is useful as a prophylactic agent in those subjects prone to multiple organ failure (MOF) such as burn victims, multiple trauma patients, hypoxic neonates, acute respiratory distress syndrome patients, and necrotizing enterocolitis patients.

Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect

Growing community of inventors

Ciudad Habana, Cuba

Diana Garcia Del Barco Herrera